公开(公告)号：US20240358831A1

公开(公告)日：2024-10-31

申请号：US18685736

申请日：2022-08-24

Applicant: IMMATICS US, INC. ,  Immatics Biotechnologies GmbH

Inventor： Stefanie SPALT ,  Claudia WAGNER ,  Dominik MAURER ,  Heiko SCHUSTER ,  Steffen WALTER

IPC: A61K39/00 ,  C07K14/74 ,  C12N5/0783

CPC classification number: A61K39/4632 ,  A61K39/4611 ,  C07K14/70539 ,  C12N5/0636 ,  C12N2502/11

Abstract: The present invention relates to a method for selecting an immune cell expressing on its surface an antigen-binding protein specifically binding to a complex of a peptide A (PA) and a Major Histocompatibility Complex (MHC) molecule, comprising the steps of (i) providing a plurality of immune cells expressing different antigen-binding proteins; (ii) contacting the plurality of immune cells with a first composition comprising a complex 1A, comprising a MHC molecule 1 (M1) and a peptide A (PA), and a complex 1X, comprising M1 and a peptide B (PB); (iii) contacting the plurality of immune cells with a second composition comprising a complex 2A, comprising a MHC molecule 2 (M2) and PA, and a complex 2X, comprising M2 and a peptide C (PC); (iv) selecting from the plurality of immune cells a cell expressing an antigen binding protein that specifically binds to complex 1A, wherein complexes 1X and 2X, but not 1A and 2A, dissociate upon stimulation with a defined chemical or physical stimulus; and wherein the amino acid sequences of PB and PC differ in at least one amino acid. The invention further relates to an immune cell selected by the method according to the invention, a method of treatment using said immune cell, a kit for selecting a cell expressing on its surface an antigen-binding protein, and a peptide suitable for use in the method according to the invention.

公开(公告)号：US20240092933A1

公开(公告)日：2024-03-21

申请号：US18511308

申请日：2023-11-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Gabriele PSZOLLA ,  Martin HOFMANN ,  Meike HUTT ,  Sebastian BUNK ,  Felix UNVERDORBEN ,  Frank SCHWOEBEL ,  Dominik MAURER ,  Maike JAWORSKI ,  Claudia WAGNER ,  Florian SCHWOERER ,  Heiko SCHUSTER

IPC: C07K16/30 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K16/30 ,  C07K16/2809 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92

Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

公开(公告)号：US20220184193A1

公开(公告)日：2022-06-16

申请号：US17681268

申请日：2022-02-25

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Claudia WAGNER ,  Julia LEIBOLD ,  Colette SONG

IPC: A61K39/00 ,  A61P35/00 ,  G16B20/20 ,  A61K35/17 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220098270A1

公开(公告)日：2022-03-31

申请号：US17553017

申请日：2021-12-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Leonie ALTEN ,  Dominik MAURER ,  Sebastian BUNK ,  Claudia WAGNER ,  Mathias FERBER

IPC: C07K14/725 ,  C07K14/47 ,  A61K35/17 ,  C12N5/0783 ,  C12N5/10 ,  A61K35/12

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20210145952A1

公开(公告)日：2021-05-20

申请号：US17150617

申请日：2021-01-15

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Claudia WAGNER ,  Julia LEIBOLD ,  Colette SONG

IPC: A61K39/00 ,  A61P35/00 ,  G16B20/20 ,  A61K35/17 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200316183A1

公开(公告)日：2020-10-08

申请号：US16911069

申请日：2020-06-24

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C12N15/115 ,  C07K14/47 ,  C07K16/18 ,  C07K14/74

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200268861A1

公开(公告)日：2020-08-27

申请号：US16851627

申请日：2020-04-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/74 ,  C07K16/18 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200254106A1

公开(公告)日：2020-08-13

申请号：US16826946

申请日：2020-03-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Leonie ALTEN ,  Sebastian BUNK ,  Dominik MAURER ,  Claudia WAGNER

IPC: A61K47/55 ,  A61K47/64 ,  A61P35/00 ,  A61K35/17 ,  A61K38/17 ,  A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/725 ,  C12N5/00 ,  C12N15/85

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (MAGEA1). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20200147192A1

公开(公告)日：2020-05-14

申请号：US16748350

申请日：2020-01-21

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/74 ,  C07K16/18 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20250122302A1

公开(公告)日：2025-04-17

申请号：US18989486

申请日：2024-12-20

Applicant: Immatics Biotechnologies GmbH

Inventor： Sara YOUSEF ,  Fabian BRUNK ,  Andreas MORITZ ,  Sebastian BUNK ,  Claudia WAGNER ,  Dominik MAURER ,  Felix UNVERDORBEN

IPC: C07K16/30 ,  C07K14/725 ,  G01N33/574

Abstract: The present invention provides an antigen binding protein specifically binding to a CT45 antigenic peptide that is in a complex with a major histocompatibility complex (MHC) protein, wherein the CT45 antigenic peptide comprises or consists of the amino acid sequence of SEQ ID NO: 138 (KIFEMLEGV) and wherein the antigen binding protein comprises a first polypeptide comprising a variable domain VA comprising complementarity determining regions CDRa1, CDRa2 and CDRa3 and a second polypeptide comprising a variable domain VB comprising CDRb1, CDRb2 and CDRb3. Also provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins. The invention further provides the antigen binding proteins for use in medicine and a method of producing the antigen binding protein.